Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.A leadership shakeup at what was once Europe's most valuable company is likely to be cemented Friday as Novo Nordisk's controlling shareholder tightens it's grip on the weight-loss drugmaker, even as minority shareholders express discontent.Novo has found itse ...